P2-engineered exosomes carrying curcumin alleviate cognitive decline in AD-like mice by targeting microglia

Effective treatment for Alzheimer's disease (AD) and other neuroinflammatory conditions is hampered by the blood-brain barrier (BBB), which restricts drug access to the brain. While natural exosomes show promise as drug carriers due to their ability to cross the BBB, their lack of specific targeting leads to undesirable off-target effects and reduced efficacy. There's a critical need for targeted delivery systems that can precisely deliver anti-inflammatory agents to specific brain cells like microglia to modulate neuroinflammation.

Researchers constructed a novel drug delivery system, P2-Exo-Cur, by engineering exosomes to display the P2 peptide on their surface, enabling targeted delivery of curcumin to microglia. The P2 peptide specifically binds to the NCAM protein on microglia. They evaluated P2-Exo-Cur's efficiency in delivering curcumin to microglia both in vitro and in vivo. The therapeutic effects were assessed in lipopolysaccharide (LPS)-induced inflammatory BV2 cell models, measuring M1 phenotype polarization and pro-inflammatory cytokine secretion. Finally, the technology's potential was validated in the 5xFAD mouse model of AD.

The engineered P2-Exo-Cur demonstrated a nanoscale membrane structure and efficiently delivered curcumin to microglia both in vitro and in vivo. This targeted delivery approach successfully overcame off-target effects. In LPS-induced BV2 cell models, treatment with P2-Exo-Cur significantly suppressed the polarization of BV2 cells toward the M1 phenotype, a pro-inflammatory state. > Furthermore, P2-Exo-Cur treatment significantly reduced the secretion of pro-inflammatory cytokines in these activated BV2 cells. The study also validated the excellent therapeutic potential of P2-Exo-Cur in the 5xFAD mouse model, where it alleviated cognitive decline without causing significant adverse effects, confirming its beneficial effects in AD treatment.